Drug intelligence / Profile preview

ALN-2232

Development stage: Phase 2
Lead developer: Alnylam Pharmaceuticals
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

ALN-2232 is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals for the treatment of obesity and weight management. It specifically targets the activin A receptor type 1C (ACVR1C), also known as ALK7 (activin receptor-like kinase 7), in adipose tissue. By utilizing small interfering RNA (siRNA) technology, ALN-2232 silences the messenger RNA (mRNA) encoding the ACVR1C protein, which is involved in regulating adipocyte function and energy homeostasis. The drug is currently in the preclinical stage of development and represents Alnylam's first adipose-directed target in their metabolic disease portfolio.

Targets

ACVR1C (Activin A Receptor Type 1C)

Beyond the preview

Go deeper on ALN-2232.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALN-2232.

Explore the full profile